CONNEQT Health Limited (ASX:CQT) has spent 2025 reintroducing itself. The company that spent years trading as CardieX Limited under the ticker CDX has adopted the name of its best-known product — the CONNEQT Pulse — and now carries a new ASX code, CQT. The rebrand is more than cosmetic: it reframes a decades-old vascular-science business around a single consumer-facing device and the digital services management hopes will grow alongside it.

The timing is deliberate. In a mid-December market update, CONNEQT Health told shareholders that Pulse sales had reached record levels in the December quarter, extending a run of commercial momentum that has coincided with a string of United States product awards. For a micro-cap valued at roughly A$28 million, the update matters — but so does the harder question of whether one-off device sales can evolve into the kind of recurring revenue that investors typically pay a premium for.

From CardieX to CONNEQT Health: what the rebrand signals

The corporate history here is important, and easy to muddle. There is no separate company called “CONNEQT Health” that has floated independently of CardieX. Rather, CardieX Limited has renamed itself CONNEQT Health Limited and changed its ASX ticker from CDX to CQT. The underlying business, its SphygmoCor arterial-analysis heritage and its listing all carry through; only the badge on the door has changed.

That heritage is the company's calling card. SphygmoCor technology, which underpins the CONNEQT Pulse, draws on more than 50 years of cardiovascular research and has been used in clinical and research settings to measure central blood pressure and arterial-stiffness biomarkers. The Pulse packages that capability into an FDA-cleared device the company markets for at-home use — a positioning management argues sets it apart from conventional cuff monitors and consumer wearables.

Inside the December quarter: record Pulse sales and a subscription pivot

According to the company's December-quarter sales update, Pulse sales exceeded internal projections, and the period was accompanied by a run of consumer recognition, including inclusion in AARP's “Best of 2026” list and a “Best Advanced Monitor” nod from the National Council on Aging. The device has also drawn coverage from outlets such as Wired and the BBC and featured at CES. These are marketing achievements rather than audited revenue figures, and investors will want to see the detail confirmed in the formal quarterly cash-flow report.

The more strategic shift is the move toward recurring revenue. The consumer version of the Pulse connects to a companion app and subscription service, and management's stated ambition is to layer software and data services on top of hardware sales. If that model gains traction it could smooth the lumpy, campaign-driven revenue that has characterised the business — but on the latest disclosures recurring revenue remains a developing story rather than a proven earnings base, and the company has not yet published a settled recurring-revenue run-rate.

A large and growing cardiovascular-monitoring market

The opportunity CONNEQT is chasing is genuinely large. Cardiovascular disease remains the leading cause of death worldwide, and elevated blood pressure affects well over a billion adults globally. Remote patient monitoring and digital cardiovascular tools have become a focus for health systems seeking to manage chronic disease outside hospital settings, and home-based devices that capture richer arterial data than a standard cuff could, in principle, find a role in that shift.

The counterweight is that this is a crowded and well-funded field. Consumer wearables from large technology companies, established blood-pressure brands and a wave of digital-health start-ups all compete for the same clinicians, retail shelves and consumer attention. CONNEQT's differentiation rests on clinical pedigree and the specific biomarkers the Pulse measures, but converting scientific credibility into durable market share is a separate challenge.

Catalysts to watch for CQT

Several near-term catalysts will shape sentiment around CQT. The formal December-quarter cash-flow statement will show whether record sales translated into improved cash receipts and a narrower operating burn. Progress in the United States — the company's primary consumer market — including any retail, distribution or reimbursement developments, would be significant. So too would evidence that the subscription model is generating measurable recurring revenue, and any updates on the funding position given the company's modest cash base. Investors will also weigh whether the momentum in awards and media coverage feeds through into repeat orders and higher-margin services rather than simply lifting one-off unit volumes for a single reporting period.

The risks: adoption, funding, competition, execution and reimbursement

The risks are equally clear-eyed. As a micro-cap with a market value near A$28 million, CONNEQT is likely to need ongoing access to capital, and further equity raisings could dilute existing holders; a recent notice of cessation of securities is a reminder that the capital structure continues to move. Adoption risk is real — home cardiovascular devices depend on consumers valuing advanced biomarkers enough to pay a premium and, ideally, a subscription.

Competition from far larger, better-capitalised players is a persistent threat, and execution risk looms over a small team attempting to scale hardware, software and international distribution at once. Reimbursement is another open question: without clear pathways for clinicians or health systems to be paid for using the technology, uptake may lean heavily on out-of-pocket consumer spending, which is more cyclical and price-sensitive.

Conclusion: recurring revenue as the real test

For now, CONNEQT Health (ASX:CQT) presents a familiar micro-cap profile: credible science, encouraging product momentum and genuine market need, set against a small balance sheet and unproven economics. The reported record Pulse sales are a real, if unaudited, sign of demand. But the working thesis — that recurring revenue is becoming the real story — remains a hypothesis to be tested in the quarterly numbers rather than a settled fact. Whether CQT can turn a well-regarded device into a durable, subscription-backed franchise is the question that will define the year ahead.